|View printer-friendly version|
|March 16, 2017 2:00 p.m.|
|Teva Announces Launch of Authorized Generic of Minastrin® 24 Fe (norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets) in the United States|
The Authorized Generic of Minastrin® 24 Fe is an estrogen/progestin combined oral contraceptive indicated for use by women to prevent pregnancy.
This Authorized Generic of Minastrin® 24 Fe adds to Teva’s existing portfolio of more than 50 oral contraceptives. In the U.S., one of every two oral contraceptive prescriptions is filled with a product marketed by Teva.2
With nearly 600 generic medicines available, Teva has the largest
Minastrin® 24 Fe had annual sales of approximately
About the Authorized Generic of Minastrin® 24 Fe (norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets)
INDICATIONS AND USAGE
IMPORTANT SAFETY INFORMATION
Warnings and Precautions
The Authorized Generic of Minastrin® 24 Fe should not be prescribed for women with uncontrolled hypertension or hypertension with vascular disease. Women who are prediabetic or diabetic, should be monitored while using the Authorized Generic of Minastrin® 24 Fe. Alternate contraceptive methods should be considered for women with uncontrolled dyslipidemia. Patients using the Authorized Generic of Minastrin® 24 Fe who have a significant change in headaches or irregular bleeding or amenorrhea should be evaluated.
Patients should be counseled that COCs do not protect against HIV infection (AIDS) and other sexually transmitted diseases.
Teva's Safe Harbor Statement under the
This press release contains forward-looking statements, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:
and other factors discussed in our Annual Report on Form 20-F for the
1 Minastrin® is a registered trademark of
Teva Pharmaceutical Industries Ltd.